Back

Medscape, LLC

  • Breast Neoplasms

Lessons From the Real World: Treating High Risk HR+/HER2- Breast Cancer According to the Latest Evidence: A Chinese Perspective

The goal of this activity is for learners to be better able to enhance their understanding of the definition of high risk of recurrence in HR-positive/HER2-negative EBC and critically evaluate the role of current adjuvant treatment options in mitigating the risk.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.25 credits

MOC types

ABIM — Medical KnowledgeUp to 0.25 points

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Online course / module
  • Credit · Up to 0.25 credits
  • MOC · Up to 0.25 points
  • Commercial Support
  • Released
    Apr 30, 2026
  • Last day to claim credit
    May 1, 2027 7 months left